Category
Weight Loss
Compounds used in fat-loss and appetite-management protocols, including incretin (GLP-1 / GIP / glucagon) agonists and metabolic supports. This index contains 9 structured entries in the current library, including 5-Amino-1MQ, AOD-9604, Cagrilintide, L-Carnitine, MOTS-c, Retatrutide, and other entries listed below. Their recorded statuses include Approved drug, Investigational, Research peptide; those labels matter because approved-drug, investigational, reference-compound, research-peptide, and blend contexts should not be read as equivalent. Start by separating approved drugs from investigational or research entries, then compare titration structure, gastrointestinal tolerability context, and treatment duration. The weekly agents have different escalation schedules, while metabolic supports outside the incretin group use different timing and cycle patterns. Use the comparison table as a navigation aid rather than a protocol: it summarizes status, common vial format, and recorded cycle or treatment context, while each detail page remains the authoritative location for reconstitution, format-specific U-100 draws, dosing language, timing, side effects, and practical notes. When several entries appear to fit the same broad goal, compare the simplest relevant option first, confirm that its treatment style matches the intended use, and use the linked guides for measurement and cycle-planning context.
How to compare Weight Loss entries
Start by separating approved drugs from investigational or research entries, then compare titration structure, gastrointestinal tolerability context, and treatment duration. The weekly agents have different escalation schedules, while metabolic supports outside the incretin group use different timing and cycle patterns.
Peptides in Weight Loss (9)
| Peptide | Status | Common vial | Cycle length |
|---|---|---|---|
| 5-Amino-1MQ | Research peptide | 50 mg | 4-8 weeks (2-4 weeks off) |
| AOD-9604 | Research peptide | 5 mg | 8-12 weeks |
| Cagrilintide | Investigational | 5 mg | Titrated once-weekly treatment |
| L-Carnitine | Research peptide | 10 mL @ 1000 mg/mL (10,000 mg total) | 8-16 weeks |
| MOTS-c | Research peptide | 40 mg | 2-6 weeks; keep aggressive blocks short and reassess. |
| Retatrutide | Investigational | 10 mg | Titrated once-weekly treatment |
| Semaglutide | Approved drug | 10 mg | Titrated once-weekly treatment |
| Tesamorelin | Approved drug | 10 mg | 12-26 weeks |
| Tirzepatide | Approved drug | 10 mg | Titrated once-weekly treatment |
Related goal guides
Useful guides
Weight Loss FAQ
What belongs in the Weight Loss category?
Compounds used in fat-loss and appetite-management protocols, including incretin (GLP-1 / GIP / glucagon) agonists and metabolic supports.
How should Weight Loss entries be compared?
Start by separating approved drugs from investigational or research entries, then compare titration structure, gastrointestinal tolerability context, and treatment duration. The weekly agents have different escalation schedules, while metabolic supports outside the incretin group use different timing and cycle patterns.
Where are the exact dosing and U-100 details for Weight Loss entries?
Open an individual peptide page for its authoritative vial formats, dosing or titration schedule, timing, and notes. Use the linked calculator only after confirming the selected vial quantity and mix volume.